HtrA1 resensitizes multidrug-resistant hepatocellular carcinoma cells by targeting XIAP

Biomedicine and Pharmacotherapy

Volumn 70, Issue C, 2015, Pages 97-102

  Bao, Wanyuan ^a   Zhu, Feng ^a   Duan, Yunfei ^a   Yang, Yue ^a   Cai, Huihua ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Chemosensitivity; Chemotherapy resistance; Hepatocellular carcinoma; High temperature requirement A1 (HtrA1); X linked inhibitor of apoptosis protein (XIAP)

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE 9; DOXORUBICIN; FLUOROURACIL; HIGH TEMPERATURE REQUIREMENT A1 PROTEIN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN; OXALIPLATIN; SERINE PROTEINASE; TYPE II SITE SPECIFIC DEOXYRIBONUCLEASE; UNCLASSIFIED DRUG; VINCRISTINE; X LINKED INHIBITOR OF APOPTOSIS; ANTINEOPLASTIC AGENT; HTRA1 PROTEIN, HUMAN; XIAP PROTEIN, HUMAN;

AMINO ACID SEQUENCE; ARTICLE; CHEMOSENSITIVITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; ENZYME ACTIVITY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IC50; MTT ASSAY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; UPREGULATION; CARCINOMA, HEPATOCELLULAR; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; LIVER NEOPLASMS; METABOLISM;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; SERINE ENDOPEPTIDASES; TRANSFECTION; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84927555751     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.12.044     Document Type: Article

References (26)

1. Stewart B.W., Wild C. World cancer report 2014 2014, World Health Organization.
2. Shariff M.I., Cox I.J., Gomaa A.I., Khan S.A., Gedroyc W., Taylor-Robinson S.D. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Exp Rev Gastroenterol Hepatol 2009, 3:353-367.
3. Pleguezuelo M., Marelli L., Misseri M., Germani G., Calvaruso V., Xiruochakis E., et al. TACE versus TAE as therapy for hepatocellular carcinoma 2008.
4. Zumbrunn J., Trueb B. Primary structure of a putative serine protease specific for IGF-binding proteins. FEBS Lett 1996, 398:187-192.
5. De Luca A., De Falco M., Severino A., Campioni M., Santini D., Baldi F., et al. Distribution of the serine protease HtrA1 in normal human tissues. J Histochem Cytochem 2003, 51:1279-1284.
6. Zurawa-Janicka D., Skorko-Glonek J., Lipinska B. HtrA proteins as targets in therapy of cancer and other diseases. Exp Opin Ther Targets 2010, 14:665-679.
7. Chien J., Ota T., Aletti G., Shridhar R., Boccellino M., Quagliuolo L., et al. Serine protease HtrA1 associates with microtubules and inhibits cell migration. Mol Cell Biol 2009, 29:4177-4187.
8. Xia J., Wang F., Wang L., Fan Q. Elevated serine protease HtrA1 inhibits cell proliferation, reduces invasion, and induces apoptosis in esophageal squamous cell carcinoma by blocking the nuclear factor-κB signaling pathway. Tumor Biol 2013, 34:317-328.
9. Chien J., Staub J., Hu S.-I., Erickson-Johnson M.R., Couch F.J., Smith D.I., et al. A candidate tumor suppressor HtrA1 is downregulated in ovarian cancer. Oncogene 2004, 23:1636-1644.
10. Zhu F., Jin L., Luo T.-P., Luo G.-H., Tan Y., Qin X.-H. Serine protease HtrA1 expression in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2010, 9:508-512.
11. Chien J., Aletti G., Baldi A., Catalano V., Muretto P., Keeney G.L., et al. Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. J Clin Invest 2006, 116:1994-2004.
12. He X., Khurana A., Maguire J.L., Chien J., Shridhar V. HtrA1 sensitizes ovarian cancer cells to cisplatin-induced cytotoxicity by targeting XIAP for degradation. Int J Cancer 2012, 130:1029-1035.
13. Almquist K.C., Loe D.W., Hipfner D.R., Mackie J.E., Cole S.P., Deeley R.G. Characterization of the Mr 190,000 multidrug resistance protein (MRP) in drug-selected and transfected human tumor cells. Cancer Res 1995, 55:102-110.
14. Sela S., Husain S.R., Pearson J.W., Longo D.L., Rahman A. Reversal of multidrug resistance in human colon cancer cells expressing the human MDR1 gene by liposomes in combination with monoclonal antibody or verapamil. J Natl Cancer Inst 1995, 87:123-128.
15. Borst P., Evers R., Kool M., Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000, 92:1295-1302.
16. Zhu H., Liu Z., Tang L., Liu J., Zhou M., Xie F., et al. Reversal of P-gp and MRP1-mediated multidrug resistance by H6, a gypenoside aglycon from Gynostemma pentaphyllum, in vincristine-resistant human oral cancer (KB/VCR) cells. Eur J Pharmacol 2012, 696:43-53.
17. Bilim V., Kasahara T., Hara N., Takahashi K., Tomita Y. Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug-resistant TCC in vitro. Int J Cancer 2003, 103:29-37.
18. Chen J., Xiao X.-Q., Deng C.-M., Su X.-S., Li G.-Y. Downregulation of xIAP expression by small interfering RNA inhibits cellular viability and increases chemosensitivity to methotrexate in human hepatoma cell line HepG2. J Chemother 2006, 18:525-531.
19. Arbab I.A., Looi C.Y., Abdul A.B., Cheah F.K., Wong W.F., Sukari M.A., et al. Dentatin induces apoptosis in prostate cancer cells via Bcl-2, Bcl-xL, survivin downregulation, caspase-9,-3/7 activation, and NF-κB inhibition. Evid Based Complement Altern Med 2012.
20. Zheng L.H., Bao Y.L., Wu Y., Yu C.L., Meng X., Li Y.X. Cantharidin reverses multidrug resistance of human hepatoma HepG2/ADM cells via down-regulation of P-glycoprotein expression. Cancer Lett 2008, 272:102-109.
21. Denizot F., Lang R. Rapid colorimetric assay for cell growth and survival: modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 1986, 89:271-277.
22. Chou T.-C., Guan Y., Soenen D.R., Danishefsky S.J., Boger D.L. Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice. Cancer Chemother Pharmacol 2005, 56:379-390.
23. Wang X. Association of HTRA1 gene mutation in a family with CARASIL and TGF-β signaling in vascular smooth muscle cells 2012, Second Military Medical University.
24. Palmer D.C., Reger R.N., Garvin L.M., Frasheri D., Ji Y., Franco Z.J., et al. CS11-4. Cish degradation of Htra1 regulates TGF-b signaling. Cytokine 2011, 56:60.
25. Sun C., Cai M., Meadows R.P., Xu N., Gunasekera A.H., Herrmann J., et al. NMR structure and mutagenesis of the third Bir domain of the inhibitor of apoptosis protein XIAP. J Biol Chem 2000, 275:33777-33781.
26. Catalano V., Mellone P., d'Avino A., Shridhar V., Staccioli M.P., Graziano F., et al. HtrA1, a potential predictor of response to cisplatin-based combination chemotherapy in gastric cancer. Histopathology 2011, 58:669-678.